SS1
MCID: SRC025
MIFTS: 71

Sarcoidosis 1 (SS1)

Categories: Bone diseases, Endocrine diseases, Eye diseases, Genetic diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Sarcoidosis 1

MalaCards integrated aliases for Sarcoidosis 1:

Name: Sarcoidosis 1 57 73
Sarcoidosis 57 11 19 58 75 73 53 41 43 14 63 71 31 33
Boeck Sarcoid 57 11 58 73
Besnier-Boeck-Schaumann Disease 58 73 33
Sarcoidosis, Susceptibility to, 1 57 5
Ss1 57 73
Hutchinson-Boeck Disease or Syndrome 33
Schaumann's Disease or Syndrome 33
Lymphogranulomatosis 11
Hodgkin Disease 71
Boeck's Disease 33
Boeck's Sarcoid 33

Characteristics:


Inheritance:

Sarcoidosis 1: Autosomal dominant 57
Sarcoidosis: Multigenic/multifactorial 58

Prevelance:

Sarcoidosis: 6-9/10000 (United States, Switzerland, Czech Republic) 1-5/10000 (Worldwide, Ireland, Europe, France, Finland, Italy, Sweden, Norway, Norway, Canada, Guadeloupe) 1-9/100000 (Croatia, United Kingdom, Spain, Denmark, Switzerland, Greece, Greece, Iceland, Czech Republic, Australia, Japan, Japan, France, Taiwan, Province of China, Guadeloupe) 1-9/1000000 (Korea, Republic of, Singapore, Portugal, Uruguay) >1/1000 (Sweden) 58

Age Of Onset:

Sarcoidosis: Adolescent,Adult,Childhood,Elderly 58

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
generalized fatigue
onset usually before age 40 years
systemic granulomatous disease
u.s. frequency higher in blacks than whites


Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare endocrine diseases


External Ids:

Disease Ontology 11 DOID:11335
OMIM® 57 181000
ICD9CM 34 135
MeSH 43 D012507
NCIt 49 C34995
SNOMED-CT 68 154425004
ICD10 31 D86 D86.9
MESH via Orphanet 44 D012507
ICD10 via Orphanet 32 D86.0 D86.1 D86.2 more
UMLS via Orphanet 72 C0036202
Orphanet 58 ORPHA797
UMLS 71 C0019829 C0036202

Summaries for Sarcoidosis 1

MedlinePlus: 41 Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body. No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include: Cough Shortness of breath Weight loss Night sweats Fatigue Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Sarcoidosis 1, also known as sarcoidosis, is related to blau syndrome and cardiac sarcoidosis, and has symptoms including snoring and coughing. An important gene associated with Sarcoidosis 1 is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Azathioprine and Pirfenidone have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and eye, and related phenotypes are fatigue and fever

PubMed Health : 63 Sarcoidosis: Sarcoidosis (sar-koy-DO-sis) is a disease of unknown cause that leads to inflammation. This disease affects your body’s organs. Normally, your immune system defends your body against foreign or harmful substances. For example, it sends special cells to protect organs that are in danger. These cells release chemicals that recruit other cells to isolate and destroy the harmful substance. Inflammation occurs during this process. Once the harmful substance is gone, the cells and the inflammation go away. In people who have sarcoidosis, the inflammation doesn't go away. Instead, some of the immune system cells cluster to form lumps called granulomas (gran-yu-LO-mas) in various organs in your body.

Orphanet: 58 A rare multisystemic, autoinflammatory disorder of unknown etiology characterized by the formation of immune, non-caseating granulomas in any organ(s), leading to variable clinical symptoms and severity. Clinical presentation is typically with persistent dry cough, eye or skin manifestations, peripheral lymph nodes, fatigue, weight loss, fever or night sweats, and Löfgren syndrome.

UniProtKB/Swiss-Prot: 73 An idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved.

Disease Ontology: 11 A hypersensitivity reaction type IV disease characterized by the growth of collections of inflammatory cells (granulomas) in multiple organs.

Wikipedia: 75 Sarcoidosis (also known as Besnier-Boeck-Schaumann disease) is a disease involving abnormal collections... more...

More information from OMIM: 181000

Related Diseases for Sarcoidosis 1

Diseases in the Sarcoidosis 1 family:

Sarcoidosis 2 Sarcoidosis 3

Diseases related to Sarcoidosis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1899)
# Related Disease Score Top Affiliating Genes
1 blau syndrome 33.2 TNF NOD2 IL1B
2 cardiac sarcoidosis 33.2 TNF BTNL2 ACE
3 skin sarcoidosis 33.1 TNF IFNG CCR6 ACE
4 melkersson-rosenthal syndrome 32.6 TNF NOD2 ACE
5 pars planitis 32.5 HLA-DRB1 CCR6 ACE
6 interstitial lung disease 32.3 TNF SERPINA3 IL1B IL18 IFNG CCR6
7 retinal vasculitis 32.3 TNF CCR6 CCL2 ACE
8 uveoparotid fever 32.2 HLA-DRB1 ACE
9 intermediate uveitis 32.2 TNF IL2RA IFNG CXCR3 CCR6 ACE
10 uveitis 32.1 TNF NOD2 IL2RA IL1B IFNG HLA-DRB1
11 erythema nodosum 31.9 TNF NOD2 IL1B IFNG
12 extrinsic allergic alveolitis 31.9 TNF IL2RA IL18 CXCR3 CCR6 CCL3
13 pulmonary fibrosis 31.9 IL1B CXCR3 CCL3 CCL2 CCL18
14 lung disease 31.8 TNF SERPINA3 SCGB1A1 IL1B IFNG CXCR3
15 vasculitis 31.7 TNF SERPINA3 IL1B HLA-DRB1 CCL2
16 anterior uveitis 31.7 TNF SERPINA3 IL1B IFNG HLA-DRB1 CCR6
17 interstitial nephritis 31.6 TNF CCR6 ACE
18 choroiditis 31.5 TNF IFNG CCR6 ACE
19 posterior uveitis 31.5 TNF IL2RA CCR6 ACE
20 myocarditis 31.5 TNF IL1B IL18 IL12RB1 IFNG CXCL9
21 interstitial lung disease 2 31.5 TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
22 spondyloarthropathy 1 31.4 TNF NOD2 IL1B CCR6
23 berylliosis 31.4 IFNG HLA-DRB1 ACE
24 exanthem 31.4 TNF IL1B IL18 IFNG CCR6 ACE
25 primary biliary cholangitis 31.4 TNF IL1B IL12RB1 HLA-DRB1 CCR6 CCL2
26 chronic granulomatous disease 31.4 TNF IL1B IL12RB1 IFNG
27 glomerulonephritis 31.4 TNF SCGB1A1 IL1B CXCL9 CCL2 ACE
28 pulmonary tuberculosis 31.4 TNF IL2RA IL1B IL18 IL12RB1 IFNG
29 panuveitis 31.4 TNF SERPINA3 NOD2 IL1B IFNG HLA-DRB1
30 alopecia 31.4 TNF IL1B IFNG HLA-DRB1
31 autoimmune disease 31.4 TNF IL2RA IL1B IL18 IFNG HLA-DRB1
32 systemic scleroderma 31.4 TNF IL1B HLA-DRB1 CCR6 CCL2 CCL18
33 crohn's disease 31.4 TNF SERPINA3 NOD2 IL1B IL18 IFNG
34 chronic beryllium disease 31.4 IL18 IFNG HLA-DRB1
35 myositis 31.4 TNF SERPINA3 IL1B IFNG HLA-DRB1
36 respiratory failure 31.4 TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
37 inflammatory bowel disease 1 31.4 TNF NOD2 IL1B CCR6
38 macular retinal edema 31.4 TNF IL1B CCL2 ACE
39 allergic disease 31.3 TNF SERPINA3 IL1B IFNG CCR6 CCL3
40 leprosy 3 31.3 TNF SERPINA3 NOD2 IL1B IL18 IFNG
41 thyroiditis 31.3 TNF IL1B IFNG HLA-DRB1
42 bronchiectasis 31.3 TNF SERPINA3 IL1B IFNG
43 aspergillosis 31.3 TNF NOD2 IL1B IL18 IFNG HLA-DRB1
44 kidney disease 31.3 TNF IL1B IL18 IFNG CCL2 ACE
45 portal hypertension 31.3 TNF CCR6 ACE
46 pneumoconiosis 31.3 TNF IL1B HLA-DRB1 CCL2
47 histoplasmosis 31.3 TNF IL12RB1 IFNG HLA-DRB1 CCR6
48 cryptococcosis 31.3 TNF IFNG CCR6
49 optic nerve disease 31.2 TNF SERPINA3 IL1B HLA-DRB1 CCR6 ACE
50 spondylitis 31.2 TNF NOD2 IL1B IFNG HLA-DRB1 CCR6

Graphical network of the top 20 diseases related to Sarcoidosis 1:



Diseases related to Sarcoidosis 1

Symptoms & Phenotypes for Sarcoidosis 1

Human phenotypes related to Sarcoidosis 1:

58 30 (show top 50) (show all 101)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
2 fever 58 30 Frequent (33%) Frequent (79-30%)
HP:0001945
3 thrombocytopenia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001873
4 dyspnea 58 30 Frequent (33%) Frequent (79-30%)
HP:0002094
5 joint swelling 58 30 Frequent (33%) Frequent (79-30%)
HP:0001386
6 uveitis 58 30 Frequent (33%) Frequent (79-30%)
HP:0000554
7 cough 58 30 Frequent (33%) Frequent (79-30%)
HP:0012735
8 chest pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0100749
9 weight loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0001824
10 leukopenia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001882
11 erythema nodosum 58 30 Frequent (33%) Frequent (79-30%)
HP:0012219
12 increased t cell count 58 30 Frequent (33%) Frequent (79-30%)
HP:0100828
13 facial palsy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010628
14 cataract 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000518
15 hepatomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002240
16 blindness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000618
17 renal insufficiency 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000083
18 portal hypertension 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001409
19 alopecia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001596
20 bronchiectasis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002110
21 nephrolithiasis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000787
22 pneumothorax 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002107
23 diabetes insipidus 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000873
24 subcutaneous nodule 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001482
25 emphysema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002097
26 glaucoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000501
27 nephrocalcinosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000121
28 hypercalciuria 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002150
29 hypercalcemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003072
30 peripheral neuropathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0009830
31 hepatic failure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001399
32 abnormality of the gastrointestinal tract 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011024
33 bone cyst 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012062
34 keratoconjunctivitis sicca 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001097
35 hypopigmentation of the skin 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001010
36 heart block 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012722
37 lymphadenopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002716
38 upper airway obstruction 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002781
39 pulmonary fibrosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002206
40 proximal muscle weakness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003701
41 tubulointerstitial nephritis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001970
42 dacryocystitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000620
43 scarring 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100699
44 skin plaque 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0200035
45 chylothorax 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010310
46 ventricular tachycardia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004756
47 hyperpigmentation of the skin 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000953
48 maculopapular exanthema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0040186
49 abnormal reproductive system morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012243
50 abnormal liver parenchyma morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030146

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Head And Neck Eyes:
photophobia
glaucoma
uveitis
iridocyclitis
blurred vision
more
Abdomen Gastrointestinal:
anorexia
associated inflammatory bowel disease

Laboratory Abnormalities:
hypercalciuria
elevated erythrocyte sedimentation rate (esr)
elevated serum angiotensin-converting enzyme (ace)
positive kveim-siltzbach skin test
mononuclear cell noncaseating granulomatous inflammation on biopsy (lung, skin, lip)

Immunology:
generalized lymphadenopathy
hyperglobulinemia
activated t-helper cells
activated mononuclear phagocytes
exaggerated cellular immune processes

Head And Neck Mouth:
enlarged salivary glands

Abdomen Liver:
hepatomegaly may occur
elevated liver function tests may occur

Neurologic Central Nervous System:
neurosarcoidosis (5-16% of patients)

Metabolic Features:
fever

Respiratory:
dyspnea
cough

Growth Weight:
weight loss

Skeletal:
polyarthritis
bone cysts

Respiratory Lung:
bilateral hilar adenopathy
pulmonary parenchymal infiltration
pulmonary function tests show interstitial lung disease

Abdomen Spleen:
splenomegaly may occur

Hematology:
bone marrow involvement may cause pancytopenia

Clinical features from OMIM®:

181000 (Updated 08-Dec-2022)

UMLS symptoms related to Sarcoidosis 1:


snoring; coughing

MGI Mouse Phenotypes related to Sarcoidosis 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 ACE BTNL2 CCL18 CCL2 CCL3 CCR6
2 neoplasm MP:0002006 9.92 ACE BTNL2 CCL2 CXCR3 IFNG IL1B
3 immune system MP:0005387 9.91 ACE BTNL2 CCL18 CCL2 CCL3 CCR6
4 digestive/alimentary MP:0005381 9.81 BTNL2 CCL18 CCL2 CCL3 IFNG IL18
5 hematopoietic system MP:0005397 9.55 ACE BTNL2 CCL18 CCL2 CCL3 CCR6

Drugs & Therapeutics for Sarcoidosis 1

PubMed Health treatment related to Sarcoidosis 1: 63

Not everyone who has sarcoidosis needs treatment . Sometimes the disease goes away on its own. Whether you need treatment and what type of treatment you need depend on your signs and symptoms, which organs are affected, and whether those organs are working well. If the disease affects certain organs —such as your eyes , heart , or brain —you'll need treatment even if you don't have any symptoms. In either case, whether you have symptoms or not, you should see your doctor for ongoing care. He or she will want to check to make sure that the disease isn't damaging your organs . For example, you may need routine lung function tests to make sure that your lungs are working well. If the disease isn't worsening, your doctor may watch you closely to see whether the disease goes away on its own. If the disease does start to get worse, your doctor can prescribe treatment . The goals of treatment include: Relieving symptoms Improving organ function Controlling inflammation and reducing the size of granulomas (inflamed lumps) Preventing pulmonary fibrosis (lung scarring ) if your lungs are affected Your doctor may prescribe topical treatments and/or medicines to treat the disease.

Drugs for Sarcoidosis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 484)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
3
Riociguat Approved Phase 4 625115-55-1 11304743
4
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
5
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
6
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959 6435378 5311181
7
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
8
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
9
Cisplatin Approved Phase 4 15663-27-1 2767 5702198 441203
10
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
11
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
14
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
15
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
17
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
18
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
19
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
20
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
21
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
23
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
24 Central Nervous System Stimulants Phase 4
25 Dopamine Uptake Inhibitors Phase 4
26 Dopamine Agents Phase 4
27
Dexmethylphenidate Hydrochloride Phase 4
28 Anesthetics, Intravenous Phase 4
29 Anesthetics, General Phase 4
30 Protective Agents Phase 4
31 Radiation-Protective Agents Phase 4
32 Phosphodiesterase Inhibitors Phase 4
33 Vasodilator Agents Phase 4
34 Platelet Aggregation Inhibitors Phase 4
35 Antioxidants Phase 4
36
Vitamin D2 Phase 4 3249
37 Calciferol Phase 4
38 Ergocalciferols Phase 4
39 Citrate Phase 4
40 Folic Acid Antagonists Phase 4
41 Folate Phase 4
42 Vitamin B9 Phase 4
43 Vitamin B Complex Phase 4
44
Methylprednisolone Acetate Phase 4 584547
45
Triamcinolone hexacetonide Phase 4
46
Triamcinolone diacetate Phase 4
47
Triamcinolone Acetonide Phase 4 6436
48
Apremilast Approved, Investigational Phase 2, Phase 3 608141-41-9 10151715 11561674
49
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030
50
Bosentan Approved, Investigational Phase 2, Phase 3 147536-97-8 104865

Interventional clinical trials:

(show top 50) (show all 1013)
# Name Status NCT ID Phase Drugs
1 ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS) Unknown status NCT02188017 Phase 4 Acthar gel
2 Pirfenidone for Progressive Fibrotic Sarcoidosis Unknown status NCT03260556 Phase 4 Pirfenidone;Placebos
3 A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension Unknown status NCT02625558 Phase 4 Riociguat;Placebo
4 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Unknown status NCT01830959 Phase 4 Roflumilast;Placebo
5 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
6 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Unknown status NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
7 A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis Completed NCT03320070 Phase 4 Acthar Gel;Placebo
8 Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00403650 Phase 4 Iloprost
9 Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel Completed NCT02298491 Phase 4 H.P. Acthar Gel
10 d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis Completed NCT03549598 Phase 4 68Ga-DOTATATE PET/CT;18FDG PET/CT scan;13NH3 PET/CT scan
11 Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects. Completed NCT00361387 Phase 4 d-methylphenidate
12 Target-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial. Completed NCT02246023 Phase 4
13 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial. Completed NCT01658280 Phase 4
14 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab Vedotin
15 The PREDMETH Trial: Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis - A Randomized Controlled Trial Recruiting NCT04314193 Phase 4 Methotrexate;Prednisolone
16 Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled Trial Recruiting NCT03265405 Phase 4 Low dose prednisolone;Medium dose prednisolone
17 A Prospective Multi-center Study for the Treatment of Chinese Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Using a Modified COG Strategy Recruiting NCT04726501 Phase 4
18 Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
19 Enhancing Effect on Tumour Apoptosis With the Combined Use of Pentoxifylline Plus Chemotherapeutical Agents in Pediatrics and AYA Patients With Hodgkin´s Lymphoma Recruiting NCT05490953 Phase 4 Pentoxifylline;Placebo
20 Vitamin D Homeostasis in Sarcoidosis Active, not recruiting NCT03621553 Phase 4 Ergocalciferol;Placebo;Calcium Citrate with Vitamin D2
21 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Active, not recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
22 Use of CXCL9 as a Biomarker of Acthar Efficacy Not yet recruiting NCT02523092 Phase 4 Acthar gel
23 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
24 Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE Terminated NCT00918554 Phase 4 Methotrexate;Placebo
25 CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial Withdrawn NCT01210677 Phase 4 Prednisone
26 ACTHAR Therapy for Central Nervous System Sarcoidosis Withdrawn NCT02920710 Phase 4 Repository Corticotropin Injection
27 ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial Unknown status NCT02348905 Phase 2, Phase 3 ACTHAR Gel 40 units twice weekly;ACTHAR Gel 80 units twice weekly.
28 ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study Unknown status NCT02155803 Phase 2, Phase 3 ACTHAR Gel (adrenocorticotropic hormone)
29 Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Unknown status NCT02824419 Phase 2, Phase 3 Methionine;DOTANOC
30 Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis Unknown status NCT01920919 Phase 3 Dexamethasone;Placebo
31 Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
32 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
33 HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET Unknown status NCT00736320 Phase 3 ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)
34 Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
35 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
36 The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis Completed NCT00794274 Phase 2, Phase 3 CC-100004
37 Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial. Completed NCT02200146 Phase 3 Prednisone;Hydroxychloroquine + Prednisone
38 Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES STUDY) Completed NCT03704610 Phase 3 Infliximab;Placebo
39 Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis Completed NCT00555347 Phase 2, Phase 3 Armodafinil;Placebo
40 Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00851929 Phase 2, Phase 3 Ambrisentan
41 Determination of the Efficacy and Safety of the Seasonal Influenza Vaccine Among Patients Suffering From Sarcoidosis. Completed NCT01687517 Phase 3 Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
42 Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00581607 Phase 2, Phase 3 Bosentan;Placebo
43 A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade�) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement. Completed NCT00073437 Phase 3 Infliximab
44 Endosonography (EUS and EBUS) vs Conventional Bronchoscopy for the Diagnosis of Sarcoidosis: a Randomized Trial Completed NCT00872612 Phase 3
45 Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis Completed NCT00305552 Phase 3 THALIDOMIDE
46 Tadalafil for Sarcoidosis Associated Pulmonary Hypertension Completed NCT01324999 Phase 2, Phase 3 Tadalafil
47 A Study Evaluating the Effect of the Number of Needle Revolutions Inside the Node on the Diagnostic Yield of EBUS-TBNA in Sarcoidosis Completed NCT02875756 Phase 2, Phase 3
48 "A RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPY" Completed NCT01955824 Phase 2, Phase 3 1% lignocaine;2% lignocaine
49 A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
50 A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease Completed NCT00302003 Phase 3 doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide;ifosfamide;vinorelbine tartrate;dexamethasone;etoposide phosphate;cisplatin;cytarabine

Search NIH Clinical Center for Sarcoidosis 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Ifosfamide
Lomustine
Mechlorethamine
Mechlorethamine hydrochloride
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vinblastine
Vinblastine Sulfate
Vincristine
Vincristine Sulfate
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: sarcoidosis

Genetic Tests for Sarcoidosis 1

Anatomical Context for Sarcoidosis 1

Organs/tissues related to Sarcoidosis 1:

MalaCards : Lung, Skin, Eye, Liver, Heart, Bone, T Cells

Publications for Sarcoidosis 1

Articles related to Sarcoidosis 1:

(show top 50) (show all 28890)
# Title Authors PMID Year
1
HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. 62 57 5
14508706 2003
2
Association between SLC11A1 (formerly NRAMP1) and the risk of sarcoidosis in Poland. 53 62 57
15702130 2005
3
Association between IFNA genotype and the risk of sarcoidosis. 53 62 57
15004750 2004
4
Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. 62 57
17591867 2007
5
Demographic-related variations in posterior segment ocular sarcoidosis. 62 57
15019390 2004
6
Results from a genome-wide search for predisposing genes in sarcoidosis. 62 57
11549543 2001
7
Design of a case control etiologic study of sarcoidosis (ACCESS). ACCESS Research Group. 62 57
10580780 1999
8
[Familial sarcoidosis. 4 cases from 2 families]. 62 57
3070740 1988
9
Genetic aspects of sarcoidosis. Class II histocompatibility antigens and a family study. 62 57
3827423 1987
10
Familial occurrence of sarcoidosis and Crohn's disease. 62 57
6134089 1983
11
Familial sarcoidosis with multiple occurrences in eleven families: a possible mechanism of inheritance. 62 57
1067023 1976
12
Familial sarcoidosis: a possible genetic influence. 62 57
1067024 1976
13
Familial sarcoidosis. Report of four siblings with acute sarcoidosis. 62 57
5558993 1971
14
Sarcoidosis and Crohn disease in siblings. 62 57
5558992 1971
15
SARCOIDOSIS. I. FAMILIAL OCCURRENCE. II. PSEUDOTUMOR CEREBRI AND UNUSUAL SKIN LESIONS. 62 57
14104643 1964
16
Epidemiologic investigations of sarcoidosis. III. Serum proteins; syphilis; association with tuberculosis: familial aggregation. 62 57
13874291 1961
17
Value of CT spectral imaging in the differential diagnosis of sarcoidosis and Hodgkin's lymphoma based on mediastinal enlarged lymph node: A STARD compliant article. 62 41
36451380 2022
18
Performance of Serum Angiotensin-Converting Enzyme in Diagnosing Sarcoidosis and Predicting the Active Status of Sarcoidosis: A Meta-Analysis. 62 41
36291609 2022
19
Altered transcription factor targeting is associated with differential peripheral blood mononuclear cell proportions in sarcoidosis. 62 41
36311769 2022
20
NOD2-associated diseases: Bridging innate immunity and autoinflammation. 53 62
19467619 2010
21
Sarcoidosis following Cushing's syndrome: A report of two cases and review of the literature. 53 62
20162506 2010
22
The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. 53 62
20070603 2010
23
Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. 53 62
19147181 2010
24
Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. 53 62
19910611 2010
25
CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. 53 62
19679608 2010
26
Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. 53 62
19808030 2010
27
Elevation of surfactant protein D, a pulmonary disease biomarker, in the sera of uveitis patients with sarcoidosis. 53 62
20151281 2010
28
A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene. 53 62
19854854 2010
29
Targeting the TNF-alpha pathway in sarcoidosis. 53 62
20001207 2010
30
Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case. 53 62
20022779 2010
31
Lack of association of immune-response-gene polymorphisms with susceptibility to sarcoidosis in Slovenian patients. 53 62
20082271 2010
32
Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge. 53 62
19966199 2009
33
Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. 53 62
19755199 2009
34
Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE. 53 62
20011602 2009
35
[Radiographic healing of sarcoid bone erosion]. 53 62
19756665 2009
36
Antimycobacterial immune responses in patients with pulmonary sarcoidosis. 53 62
20298409 2009
37
CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. 53 62
19386686 2009
38
Variation in the lymphotoxin-alpha/tumor necrosis factor locus modifies risk of erythema nodosum in sarcoidosis. 53 62
19225544 2009
39
Hypothesis: sarcoidosis is a STAT1-mediated disease. 53 62
19464956 2009
40
Chemokine receptors in a regulation of interstitial lung fibrosis and inflammation. 53 62
19842835 2009
41
18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. 53 62
19259660 2009
42
Cardiac infiltration in early-onset sarcoidosis associated with a novel heterozygous mutation, G481D, in CARD15. 53 62
19359344 2009
43
International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). 53 62
19585358 2009
44
Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases. 53 62
19117745 2009
45
Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. 53 62
19281539 2009
46
Atypical sarcoidosis: case reports and review of the literature. 53 62
19530510 2009
47
Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis. 53 62
19220835 2009
48
Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease. 53 62
19077082 2009
49
Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association? 53 62
19208587 2009
50
Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. 53 62
19468200 2009

Variations for Sarcoidosis 1

ClinVar genetic disease variations for Sarcoidosis 1:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HLA-DRB1 HLA-DRB1, HLA-DRB1*1101 VAR Risk Factor
14905 GRCh37:
GRCh38:

Expression for Sarcoidosis 1

Search GEO for disease gene expression data for Sarcoidosis 1.

Pathways for Sarcoidosis 1

Pathways related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 TNF SERPINA3 NOD2 IL2RA IL1B IL18
2
Show member pathways
13.84 TNF IL2RA IL1B IL18 IL12RB1 CXCR3
3
Show member pathways
13.61 TNF IL2RA IL1B IL18 IL12RB1 IFNG
4
Show member pathways
13.55 TNF IL2RA IL1B IL18 IL12RB1 IFNG
5
Show member pathways
13.36 TNF IL2RA IL1B IL18 IL12RB1 CXCR3
6
Show member pathways
13.32 TNF NOD2 IL2RA IL1B IL18 IL12RB1
7
Show member pathways
13.06 TNF IL2RA IL1B IL18 IL12RB1 CXCR3
8
Show member pathways
12.89 CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
9
Show member pathways
12.84 TNF IL2RA IL1B CXCL9 CCL3
10
Show member pathways
12.66 TNF IL2RA IL1B IL18 IL12RB1 IFNG
11
Show member pathways
12.62 CCL2 CXCL9 IFNG IL12RB1 IL18 IL1B
12 12.59 TNF IL2RA IL1B IFNG CCL2
13
Show member pathways
12.51 TNF NOD2 IL1B IL18
14
Show member pathways
12.17 TNF IL12RB1 IFNG HLA-DRB1
15 12.03 TNF IL1B IFNG CCL2
16
Show member pathways
12.01 CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
17
Show member pathways
12 IFNG IL12RB1 IL18 IL1B TNF
18 11.99 TNF IL1B IL18 CCL2
19 11.93 CCR6 CCL3 CCL2 CCL18
20
Show member pathways
11.85 IL1B IL12RB1 IFNG
21
Show member pathways
11.84 CCL3 IFNG IL12RB1 IL18 IL1B IL2RA
22
Show member pathways
11.79 TNF IL1B IFNG
23 11.76 TNF IL1B CCL2
24 11.75 TNF IL1B IFNG
25 11.73 CCL2 CCL3 IL1B TNF
26 11.72 IL2RA IL1B IFNG
27
Show member pathways
11.7 TNF IL2RA IFNG
28
Show member pathways
11.68 TNF NOD2 IL18 IL12RB1 IFNG
29
Show member pathways
11.67 TNF IL1B IFNG
30 11.62 TNF NOD2 IFNG CCL2
31 11.6 TNF IL2RA IL1B IFNG HLA-DRB1 CXCL9
32 11.58 TNF CCL3 CCL2
33 11.54 TNF IL2RA IL18 IL12RB1 IFNG HLA-DRB1
34 11.52 TNF IL1B IFNG
35 11.48 TNF IL1B IL18 IFNG CCL2
36 11.47 NOD2 IL1B IL18
37
Show member pathways
11.46 TNF IL2RA IFNG CCL3
38 11.44 TNF IL1B IL18 CCL3 CCL2
39 11.42 IL1B IFNG CXCL9
40 11.4 TNF IL1B IL18 IFNG
41 11.35 TNF IL1B IFNG HLA-DRB1
42 11.32 CCL2 IL1B TNF
43 11.31 TNF IFNG CCL3 CCL2
44 11.27 IL2RA IL18 IFNG
45 11.24 IL1B IL18 IFNG CCL2
46 11.22 IL2RA IL12RB1 IFNG
47 11.18 TNF IL2RA IL1B IL18 IL12RB1 IFNG
48 11.1 TNF IL1B IL18
49 11.07 IL2RA HLA-DRB1 CCR6
50 11.07 TNF IL1B IL18 CXCL9 CCL3 CCL2

GO Terms for Sarcoidosis 1

Cellular components related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.2 TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
2 extracellular space GO:0005615 10.07 ACE CCL18 CCL2 CCL3 CHIT1 CXCL9
3 external side of plasma membrane GO:0009897 9.58 TNF IL2RA IL12RB1 HLA-DRB1 CXCR3 CXCL9

Biological processes related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.48 CCL18 CCL2 CCL3 CCR6 CXCL9 CXCR3
2 cell-cell signaling GO:0007267 10.36 CCL18 CCL3 CXCL9 IL18 IL1B
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.33 TNF NOD2 HLA-DRB1 CCL3 CCL2 CCL18
4 cellular response to lipopolysaccharide GO:0071222 10.28 TNF NOD2 IL1B CXCL9 CCL2
5 chemotaxis GO:0006935 10.27 CCL18 CCL2 CCL3 CCR6 CXCL9 CXCR3
6 positive regulation of interleukin-6 production GO:0032755 10.26 TNF NOD2 IL1B IFNG
7 calcium-mediated signaling GO:0019722 10.25 CCL3 CCR6 CXCR3 TNF
8 positive regulation of type II interferon production GO:0032729 10.23 IL12RB1 IL18 IL1B TNF
9 defense response to Gram-positive bacterium GO:0050830 10.22 IL18 IL1B NOD2 TNF
10 cellular response to type II interferon GO:0071346 10.22 CCL18 CCL2 CCL3 IL12RB1 TNF
11 MAPK cascade GO:0000165 10.22 TNF NOD2 IL1B IL18 CCL3 CCL2
12 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.21 IL18 IL1B NOD2 TNF
13 positive regulation of interleukin-1 beta production GO:0032731 10.21 TNF NOD2 IFNG CCL3
14 neutrophil chemotaxis GO:0030593 10.21 IL1B CXCL9 CCL3 CCL2 CCL18
15 response to lipopolysaccharide GO:0032496 10.19 ACE IL1B NOD2 SCGB1A1 TNF
16 regulation of insulin secretion GO:0050796 10.18 TNF IL1B IFNG
17 protein kinase B signaling GO:0043491 10.18 TNF IL1B CCL3 CCL2
18 monocyte chemotaxis GO:0002548 10.17 CCL3 CCL2 CCL18
19 positive regulation of phagocytosis GO:0050766 10.17 TNF NOD2 IL1B IFNG
20 negative regulation of T cell proliferation GO:0042130 10.16 HLA-DRB1 IL2RA SCGB1A1
21 negative regulation of type II interferon production GO:0032689 10.16 SCGB1A1 NOD2 HLA-DRB1
22 positive regulation of nitric oxide biosynthetic process GO:0045429 10.16 TNF IL1B IFNG
23 response to bacterium GO:0009617 10.16 TNF CXCL9 CHIT1 CCL2
24 positive regulation of inflammatory response GO:0050729 10.15 TNF IL1B IL18 IFNG CCL3 ACE
25 lymphocyte chemotaxis GO:0048247 10.14 CCL3 CCL2 CCL18
26 positive regulation of activated T cell proliferation GO:0042104 10.13 IL2RA IL18 IL12RB1
27 humoral immune response GO:0006959 10.13 CCL2 CCR6 HLA-DRB1 IFNG TNF
28 cell chemotaxis GO:0060326 10.12 CXCR3 CCR6 CCL3 CCL2
29 positive regulation of chemokine production GO:0032722 10.1 IFNG IL18 IL1B TNF
30 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 10.09 NOD2 IFNG CCL2
31 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10.08 TNF IL1B IFNG
32 astrocyte activation GO:0048143 10.06 TNF IL1B IFNG
33 chemokine-mediated signaling pathway GO:0070098 10.03 CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
34 lipopolysaccharide-mediated signaling pathway GO:0031663 10.02 CCL2 CCL3 IL18 IL1B TNF
35 positive regulation of neuroinflammatory response GO:0150078 10.01 TNF IL1B IL18
36 positive regulation of NMDA glutamate receptor activity GO:1904783 9.99 IFNG CCL2
37 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.99 TNF NOD2
38 positive regulation of fever generation GO:0031622 9.98 TNF IL1B
39 sequestering of triglyceride GO:0030730 9.97 TNF IL1B
40 positive regulation of nitrogen compound metabolic process GO:0051173 9.96 TNF IFNG
41 inflammatory response GO:0006954 9.96 CCL18 CCL2 CCL3 CXCL9 CXCR3 IL18
42 negative regulation of gap junction assembly GO:1903597 9.94 IL1B ACE
43 positive regulation of vitamin D biosynthetic process GO:0060557 9.93 TNF IFNG
44 cellular response to organic cyclic compound GO:0071407 9.93 CCL2 CCL3 IL18 IL1B NOD2 TNF
45 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.88 TNF IL1B IFNG
46 immune response GO:0006955 9.62 TNF IL2RA IL1B IL18 IFNG HLA-DRB1

Molecular functions related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.63 CCL3 CCL2 CCL18
2 chemokine activity GO:0008009 9.56 CXCL9 CCL3 CCL2 CCL18
3 cytokine activity GO:0005125 9.44 TNF IL1B IL18 IFNG CXCL9 CCL3

Sources for Sarcoidosis 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....